LETTERS TO THE EDITOR

Methicillin resistant *Staphylococcus aureus* (MRSA) balanoposthitis in an insulin dependent diabetic male

EDITOR,—Balanoposthitis is a common condition affecting 11% of the male attendees at GUM clinics.1 It is an inflammation of the glans penis and the prepuce, and its causes include bacterial and yeast infections, parasitic infestations, trauma, and irritants.2 However, to our knowledge, no case has been reported to be caused by MRSA.

A 49 year old insulin dependent diabetic male presented to us an inpatient for repair of an upper jaw fracture developed a penile itch with swollen foreskin, which was difficult to retract, together with longitudinal fissures on the prepuce and subpreputial discharge. In his recent past he had had two incidents of unprotected sexual intercourse with two known females. He was clinically diagnosed as having candida balanitis and was commenced on clotrimazole cream, which did not produce a clinical response over the course of a week. The swabs taken before the commencement of clotrimazole cream failed to grow candida; however, MRSA resistant to erythromycin, penicillin, and flucloxacillin but sensitive to mupirocin was isolated.

Screening tests for chlamydia, gonorrhoea, and trichomones were negative. A 10 day course of mupirocin 2% ointment completely resolved his symptoms.

Subpreputial swab after treatment was negative.

MRSA has been well recognised cause of hospital acquired infections worldwide since it was first detected in Europe in the 1960s.3 The organism can survive for long periods in both the hospital and the home environment and can colonise the skin, nose, or throat of hospital inpatients.4 This makes the organism a potential opportunity to cause serious infections when introduced to the skin, particularly in diabetic patients with compromised skin.5

We also noted the following data: age at diagnosis, time for presentation with reinfection, the number of contacts traced and treated in the first 3 months after diagnosis. For the purpose of the study we defined reinfection as a patient testing positive for chlamydia 30 days or more after the completion of treatment. We also looked at the genital chlamydia treatment protocols in both clinics.

A total of 540 female patients were diagnosed with chlamydia (311 at Leicester and 229 at Derby). The patients’ mean age at first episode was 22.6 years for Leicester and 23.4 years for Derby. The health advisers had made contact with 94.5% (294) in Leicester and 97.8% (224) in Derby; 85.2% (265) of the patients diagnosed at Leicester returned at 30 days or more and were retested for chlamydia compared with 87.3% (200) at Derby; 9% (24) episodes of repeat infection were identified in Leicester group compared to 17% (34) episodes in the Derby cohort. The mean period for presentation with reinfection was 9.4 months (range 3–25) at Leicester and 9.8 months (range 2–24) at Derby. At Leicester the contacts of 66.5% (207) patients were traced and treated compared to 64.6% (148) at Derby. A test of cure was performed on 282 patient in Leicester (where it was routine practice); 2.5% (seven) were found to be positive for chlamydial infection, while the test of cure was performed on 22 patients in Derby (where it was performed selectively) revealed no positive cases.

The reinfected patients 58.3% (14) at Leicester were reinfected because of failure to trace and treat their partner(s) compared to 35.5% (12) at the Derby clinic. Both clinics manage genital chlamydia with what was considered standard treatment and perform contact tracing wherever possible. Two reinfected patients from each clinic were also co-infected with gonorrhoea.

Other risk factors for reinfection—for example, ethnic origin, number of sexual partners,6 were not analysed as these data was not discernible from the notes.

This retrospective study highlights the fact that a substantial number of patients get reinfection with chlamydia despite health education and counselling by health advisers. Though the figures (66.5% and 64.6%) for partner notification and treatment were close to that proposed by the Central Audit Group (70%), the proportion of those not traced and treated is still too high. Does the message that repeat episodes of genital chlamydia are more damaging get through to our patients or do we need a new health education strategy?

Currently, as the success of treatment of genital chlamydia is evaluated by the level of contact tracing, the number of patients referred to health advisers, and number of contacts per index patient seen and treated,7 we believe it is time to evaluate outcome measures in terms of reinfection rates. Large prospective studies need to be done to elucidate this aspect of chlamydial infection management.

Contributions: PH had the original idea; EH collected and analysed the data EH and JD wrote the manuscript.

E HERIEKA
P SCHOBER
J DHAR
Department of GUM, Leicester University Hospitals Correspondence to: E Herieka, Department of GUM, Leicester Royal Infirmary, LE1 5WW, UK

Accepted for publication 8 March 2001

Chlamydia trachomatis reinfection rate: a forgotten aspect of female genital chlamydia management

EDITOR,—Hills et al8 reported that repeated episodes of infection of female genital tract with *Chlamydia trachomatis* increase the risk of hospital admission for pelvic inflammatory disease and ectopic pregnancy. The first diagnosed attack of genital infection with chlamydia presents the clinician with a unique opportunity to implement measures to minimise the risk of reinfection—that is, health promotion and contact tracing.

During April–June 1998 we reviewed the case notes of female patients who were diagnosed with genital chlamydia at Leicester Royal Infirmary and Derbyshire Royal Infirmary GUM clinics in the year 1996 for evidence of repeat episode of genital chlamydia. We also noted the following data: age for presentation with the first episode of infection, time for presentation with reinfection, test of cure if performed, co-infection with gonorrhoea, review by health adviser, contact(s) traced and treated in the first 3 months after diagnosis. For the purpose of the study we defined reinfection as a patient testing positive for genital chlamydia 30 days or more after the completion of treatment. We also looked at the genital chlamydia treatment protocols in both clinics.

A total of 540 female patients were diagnosed with chlamydia (311 at Leicester and 229 at Derby). The patients’ mean age at first episode was 22.6 years for Leicester and 23.4 years for Derby. The health advisers had made contact with 94.5% (294) in Leicester and 97.8% (224) in Derby; 85.2% (265) of the patients diagnosed at Leicester returned at 30 days or more and were retested for chlamydia compared with 87.3% (200) at Derby; 9% (24) episodes of repeat infection were identified in Leicester group compared to 17% (34) episodes in the Derby cohort. The mean period for presentation with reinfection was 9.4 months (range 3–25) at Leicester and 9.8 months (range 2–24) at Derby. At Leicester the contacts of 66.5% (207) patients were traced and treated compared to 64.6% (148) at Derby. A test of cure was performed on 282 patient in Leicester (where it was routine practice); 2.5% (seven) were found to be positive for chlamydial infection, while the test of cure was performed on 22 patients in Derby (where it was performed selectively) revealed no positive cases.

The reinfected patients 58.3% (14) at Leicester were reinfected because of failure to trace and treat their partner(s) compared to 35.5% (12) at the Derby clinic. Both clinics manage genital chlamydia with what was considered standard treatment and perform contact tracing wherever possible. Two reinfected patients from each clinic were also co-infected with gonorrhoea.

Other risk factors for reinfection—for example, ethnic origin, number of sexual partners,7 were not analysed as these data was not discernible from the notes.

This retrospective study highlights the fact that a substantial number of patients get reinfection with chlamydia despite health education and counselling by health advisers. Though the figures (66.5% and 64.6%) for partner notification and treatment were close to that proposed by the Central Audit Group (70%), the proportion of those not traced and treated is still too high. Does the message that repeat episodes of genital chlamydia are more damaging get through to our patients or do we need a new health education strategy?

Currently, as the success of treatment of genital chlamydia is evaluated by the level of contact tracing, the number of patients referred to health advisers, and number of contacts per index patient seen and treated,7 we believe it is time to evaluate outcome measures in terms of reinfection rates. Large prospective studies need to be done to elucidate this aspect of chlamydial infection management.

Contributions: PH had the original idea; EH collected and analysed the data EH and JD wrote the manuscript.

E HERIEKA
P SCHOBER
J DHAR
Department of GUM, Leicester University Hospitals Correspondence to: E Herieka, Department of GUM, Leicester Royal Infirmary, LE1 5WW, UK

Accepted for publication 8 March 2001

The Society of Apothecaries Diploma examination in Genitourinary Medicine: death of the viva voce?

EDITOR,—The London Apothecaries Diploma in Genitourinary Medicine is likely to become even more important in the near future as all specialist registrars and probably...
A pilot study was conducted to compare the sensitivity of LCR testing for genital chlamydial infection in men, taken from the meatus itself against the standard technique.

All male patients attending the GUM clinic over a 3 month period were included in the study if they had symptoms or signs compatible with chlamydia, or if a contact of a known case of chlamydia. A swab was taken from the urethra in the standard fashion. A second swab was taken from the meatus. After the sixth week of the study the order of the first and second swabs was changed, in order to evaluate any bias related to the order of the swabs. Specimens were processed using Abbott Laboratories LCx Chlamydia and handled according to the manufacturer’s guidelines.

Twenty five patients were asked to evaluate the swabs and to state which swab caused least discomfort or if there was no difference between them. A total of 208 men were recruited to the study. The overall prevalence of genital chlamydial infection in our population was 25% (52/208). A confirmed diagnosis was made by LCR in 44 cases. Of the 164 samples performed from the same man were positive for chlamydia, or if one sample was positive together with an equivocal result. There were no false positive tests using these criteria giving all methods 100% sensitivity for reducing the risk of HIV transmission

HUMPHREY BIRLEY
Department of GUM Royal Liverpool University Hospital, Liverpool L7 8XP, UK

1 Ismail A, May C. Oral exams—get them right or don’t bother. BMJ 2000;320:357.
Table 1: Unprotected anal intercourse (UAI) in the previous 3 months

<table>
<thead>
<tr>
<th>HIV negative group (n=477)</th>
<th>HIV positive group (n=126)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Main only</td>
</tr>
<tr>
<td>Men in a relationship reporting</td>
<td></td>
</tr>
<tr>
<td>Condom use UAI</td>
<td>27.1 (75)</td>
</tr>
<tr>
<td>Non-condom use UAI</td>
<td>8.0 (22)</td>
</tr>
<tr>
<td>Total</td>
<td>35.1 (97)</td>
</tr>
</tbody>
</table>

Men not in a relationship reporting

| Condom use UAI             | 2.5 (5)  | 5.0 (10) | 5.0 (10) | 1.6 (1)  | 19.0 (12) | 20.6 (13) |
| Non-condom use UAI         | 1.5 (3)  | 16.1 (32) | 17.6 (35) | 0.0 (0)  | 19.0 (12) | 19.0 (12) |
| Total                      | 4.0 (8)  | 18.6 (37) | 22.6 (45) | 1.6 (1)  | 38.1 (24) | 39.7 (24) |

*Data on UAI or relationship status missing for two HIV negative men.
†Men reporting casual UAI with a partner of unknown HIV status.
‡Men reported casual UAI with a partner of unknown or discordant HIV status. Non-condom UAI was more likely to report condom UAI with a casual partner. HIV prevention programmes need to reinforce risk reduction strategies, tailored to a person’s HIV status, while simultaneously addressing high risk sexual behaviour.

Concordance UAI whether they were in a relationship or not was confirmed in a multivariate model. With HIV status and relationship as independent variables and concordant UAI as the dependent variable, the interaction between concordant UAI and either HIV status or relationship (p=0.4) or being in a relationship (p=0.7). Concordant UAI was equally likely to report non-condomin UAI with a main partner alone (8.0%) as with a casual partner (6.5%) highlighting the continuing risk for HIV transmission between regular partners.

A mobile phone text message and Trichomonas vaginalis

Editor,—Over the past decade vast numbers of the general population have accepted the internet, email, and mobile phones. Among new patients attending our centre 70.3% (90/118) of men and 73.7% (90/133) of women provide mobile telephone numbers for contact. However, the use of mobile phones as a mechanism for contact tracing as far as I am aware has not been reported previously.

A 26 year old Afro-Caribbean man presented to our clinic and informed us that his girlfriend had attended a GUM clinic but unfortunately he did not know why. However, he informed us that he had a text message on his mobile. He duly brought up the message, which gave the woman’s clinic number and the KC60 diagnosis of C6A.

On examination there were no abnormalities seen, there were no polymorphs on microscopy, swabs for gonorrhoea, chlamydia, and trichomonas were all clear. He was treated with a 5 day course of metronidazole as per MSSVD guidelines.

If this patient had turned up without a contact slip, epidemiological treatment of trichomonas is unlikely to have been instituted and contact tracing would have been impossible. Thanks to the use of text messaging on this man’s mobile phone, appropriate treatment was initiated. Certainly patients and health advisers appreciate the security offered by mobile phones (no other family members can take the calls), the instant access, and it avoids additional paper work. The use of text messaging and mobile phones for contact tracing may be considered as an adjunct to contact slips in GU clinics.

Chaperoning male patients

Editor,—I was delighted to see the letter by Pisk et al in the journal. My staff and I were becoming alarmed at the suggestion that male patients should have a chaperone when they are being examined by a male doctor. Was common sense finally leaving the specialty? There are thousands of consultations taking place throughout the country, in both primary and secondary care, where sexual issues are discussed. These often include a genital examination, and just because there is a problem found with one or two individual patients or doctors it doesn’t mean the whole national service has to be turned upside down. Surely, the last thing an overworked, under pressure, genitourinary medicine service needs is to have another section of its skilled staff standing idly by in a room, while either a consultation or examination is taking place. I have never found any difficulty in taking the swabs on my own, and labelling the stuff myself, and have never felt the need for another person handling me things during a male examination. Indeed, I could easily see that interfering with the process at times, as there are some issues patients feel more comfortable discussing on a one to one basis, and they can feel embarrassed and hindered if there is a chaperone present.

An occasional complaint is a small price to pay for the 99.9% otherwise effective consultations that occur. It’s lovely to see work like this published, as it is a part of the evidence base that says we don’t need this.
kind of interference, and that basic common sense should prevail.

COLOM O'MAHONY
Department of Genito-Urineary Medicine,
Countess of Chester Hospital, Liverpool Road,
Chester CH2 1UL, UK


Accepted for publication 15 February 2001

Lichen sclerosus of the glans is significantly associated with penile carcinoma

EDITOR,—We read with interest the article by Riddel et al on 66 men with penile lichen sclerosus (PLS) attending a department of genitourinary medicine. In this study, the authors found no cases of malignancy.

We have previously reported a retrospective study on the incidence of cancer on 86 cases of PLS retrieved from our histopathological files over a 10 year period (1987–97). In that study, five cases showed malignant transformation—namely, squamous cell carcinoma (SCC) (three cases), in situ carcinoma (one case), and verrucous carcinoma (one case).

Since that report, we decided to interview all PLS patients in order to rule out any further malignancy that occurred over time. Of 86 patients identified, 60 were evaluated at our clinic. Among these, we found three additional patients treated with partial penectomy for invasive SCC at other institutions.

Their medical records were obtained together with paraffin embedded tissue samples to perform polymerase chain reaction (PCR) for human papillomavirus (HPV) testing. Clinical and laboratory information for these HPV positive patients (average 15 years) was compared with our study, in which a long follow-up disclosed 9.3% malignant degeneration in a series of 86 patients.

Also, the latency time was shorter in the HPV positive patients (average 15 years) compared with the HPV negative patients (average 23 years). The role of HPV in the pathogenesis of penile cancer is not fully understood. Some HPV's, such as type 16 and 18, are likely to play a part, but not all penile carcinomas are HPV positive, as shown in our study. Also, PLS is not commonly associated with HPV infection. In our study we found five patients positive for HPV 16 infection, and this may have hastened the progression towards cancer resulting in a shorter latency time. However, routine HPV testing on larger series is necessary in order to draw any definitive conclusion.

Similarly to vulvar lichen sclerosus, which has been observed to undergo malignant degeneration in 3–6% of women, a likely malignant evolution of PLS should be considered. Careful and systematic histopathological evaluation of any ulcerated or indurated plaques developing within PLS is therefore strongly recommended. The association between PLS and cancer may very well be underestimated and there is a need for further investigation that includes long term follow up and routine PCR analysis for HPV infection.

GIUSEPPE MICALI
MARIA RITA NASCA
Dermatology Clinic, University of Catania, Italy
DANIELE INNOCENZI
Dermatology Clinic, University "La Sapienza," Rome, Italy

Correspondence to: Giuseppe Micali, MD, Clinica Dermatologica, Università di Catania, Piazza S Agata La Vecure, 6, 95124 - Catania, Italy
cidermct@dimtel.nti.it


Table 1 Clinical and histopathological features of eight cases of carcinoma on penile lichen sclerosus

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Age of onset of PLS (years)</th>
<th>Age of onset of Ca (years)</th>
<th>Lag time (years)</th>
<th>Site</th>
<th>Clinical aspect of malignancy on PLS</th>
<th>Histopathology</th>
<th>PCR testing for HPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>1*</td>
<td>41</td>
<td>62</td>
<td>21</td>
<td>glans</td>
<td>fungating keratotic nodule with a white-yellowish hue slightly infiltrated verrucous papules</td>
<td>SCC, well differentiated</td>
<td>negative</td>
</tr>
<tr>
<td>2*</td>
<td>36</td>
<td>59</td>
<td>23</td>
<td>glans, coronary sulcus</td>
<td>multiple erythematous, indurated, and ulcerated plaques sharply circumscribed, erythematous, oozing, and slightly infiltrated plaque</td>
<td>SCC, well differentiated</td>
<td>positive</td>
</tr>
<tr>
<td>3*</td>
<td>41</td>
<td>55</td>
<td>14</td>
<td>glans, coronary sulcus</td>
<td>sharply circumscribed, erythematous, and ulcerated plaque</td>
<td>SCC, well differentiated</td>
<td>positive</td>
</tr>
<tr>
<td>4*</td>
<td>39</td>
<td>49</td>
<td>10</td>
<td>glans, coronary sulcus, inner aspect of the foreskin</td>
<td>sharply circumscribed, erythematous, eroded, and indurated plaque</td>
<td>SCC, undifferentiated</td>
<td>negative</td>
</tr>
<tr>
<td>5*</td>
<td>29</td>
<td>47</td>
<td>18</td>
<td>glans</td>
<td>exophytic verrucous whitish nodule sharply circumscribed, erythematous, and ulcerated plaque</td>
<td>SCC, well differentiated</td>
<td>positive</td>
</tr>
<tr>
<td>6</td>
<td>75</td>
<td>85</td>
<td>10</td>
<td>glans</td>
<td>sharply circumscribed, erythematous, eroded, and indurated plaque</td>
<td>SCC, undifferentiated</td>
<td>negative</td>
</tr>
<tr>
<td>7</td>
<td>66</td>
<td>70</td>
<td>15</td>
<td>glans, coronary sulcus</td>
<td>sharply circumscribed, erythematous, and ulcerated plaque</td>
<td>SCC, well differentiated</td>
<td>positive</td>
</tr>
<tr>
<td>8</td>
<td>33</td>
<td>67</td>
<td>34</td>
<td>glans, coronary sulcus</td>
<td>sharply circumscribed, erythematous, eroded, and indurated plaque</td>
<td>SCC, undifferentiated</td>
<td>negative</td>
</tr>
</tbody>
</table>

*Previously reported cases. 1

PLS = penile lichen sclerosus; Ca = carcinoma; PCR = polymerase chain reaction; HPV = human papillomavirus; SCC = squamous cell carcinoma; VC = verrucous carcinoma.
Table 1  Peripartum HIV test results

<table>
<thead>
<tr>
<th>Time (in weeks of gestation)</th>
<th>1 T = 12 weeks (“Booking blood”)</th>
<th>2 T = 29 weeks</th>
<th>3 T = 33 weeks (“Booking blood”)</th>
<th>4 T = 13 weeks post partum (child presents)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital where blood taken</td>
<td>X Blood was stored and retrospectively tested</td>
<td>Y Index antenatal test (serum not available for repeat retrospective testing)</td>
<td>Y Blood was stored and retrospectively tested</td>
<td>St Mary’s Postnatal test. Blood stored</td>
</tr>
<tr>
<td>HIV antibody screening tests</td>
<td>i Clear negative Detect-HIV&lt;sup&gt;i&lt;/sup&gt; Clear negative</td>
<td>i Abbott AxSYM HIV 1/2 gO&lt;sup&gt;2&lt;/sup&gt; S/CO=0.42</td>
<td>i Murex HIV 1+2&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Strong positive</td>
</tr>
<tr>
<td>HIV specific antibody tests (CPHL in-house EIA/s)</td>
<td>ii OD=0.330, CO=0.144</td>
<td>ii Wellcomecy HIV Recombinant&lt;sup&gt;4&lt;/sup&gt; OD=0.938, CO=0.252</td>
<td>ii Detect-HIV&lt;sup&gt;4&lt;/sup&gt;</td>
<td>ii OD=14.86, CO=1.00</td>
</tr>
<tr>
<td>HIV western blot&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Clear negatives, (OD/CO) HIV IgG=0.49, IgM=0.36, IgA=0.44</td>
<td>Strong positives, (OD/CO) HIV IgG=12.34, IgM=10.94, IgA=5.28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV RNA (copies/ml)</td>
<td>—</td>
<td>—</td>
<td>Strong positives for IgM and IgA: weak positive IgM (OD/CO) HIV IgG=15.41, IgM=3.14, IgA=4.18.</td>
<td></td>
</tr>
</tbody>
</table>

<sup>1</sup>Enzyme immunoassay (EIA) for detection of antibody to HIV-1 and 2. Biochem Immunossytems Inc, Montreal, Quebec, Canada.

<sup>2</sup>EIA for detection of antibody to HIV-1 (Abbott Murex), Murex Biotech Ltd, Dartford, UK.

<sup>3</sup>EIA for detection of antibodies to HIV-1 and 2. Abbott Laboratories, IL, USA.

<sup>4</sup>EIA for detection of antibodies to HIV-1 and 2 (Abbott Murex), Murex Biotech Ltd, Dartford, UK.

<sup>5</sup>Passive particulate agglutination test for detection of antibodies to HIV-1 and 2 Fujirebio Inc, Tokyo, Japan.

<sup>6</sup>Western blot for detection of antibodies to HIV antigens. GeneLogic Diagnostics, Singapore.

<sup>7</sup>Polymerase chain reaction (PCR) for quantitative detection of HIV-1 RNA. Roche Diagnostics, Branchburg, NJ, USA.

<sup>8</sup>Signal amplification nucleic acid probe assay for quantitative detection of HIV-1 RNA. Chiron Corp Emeryville, CA, USA.

### Possible false negative result

Other sera stored at various times were retrieved and tested. The results, which show seroconversion late in pregnancy, are summarised in table 1.

The HIV antibody test is usually performed at the booking visit with other routine antenatal screens. This allows the parents time to adjust to the diagnosis before delivery, to consider family planning issues and interventions to minimise the risk of mother to child transmission. In addition, mothers with advanced immunosuppression benefit from antiretroviral therapy. Although rarely reported, an HIV seronegative mother whose partner has undiagnosed HIV infection is at continued risk of infection. This may become more common in the United Kingdom as heterosexual intercourse is now the most common risk for HIV infection in newly diagnosed patients. Primary HIV infection during gestation or lactation is associated with an increased risk of mother to child transmission.

Repeat antenatal screening late in pregnancy, as is recommended for syphilis in the United States, would identify some primary HIV infections during gestation. However, if maternal infection is not prevented transmission during lactation would remain a risk and there would be significant logistic and cost implications. The extension of testing for HIV (and other infections) to the partners of pregnant women is appealing as both maternal and infant infections could be prevented (and the infected male may benefit from earlier diagnosis and treatment) but would require a fundamental change to antenatal care. A practical approach, which may prevent maternal and neonatal infection (but not identify the infected male) is to use the opportunity, when giving negative HIV, hepatitis B, and syphilis results to the mother, to discuss the sexual transmission of infections, to emphasise that the negative results cannot be extrapolated to the partner, and advocate safer sex which is commonly abandoned following conception.

**Contributors:** PG obtained samples and results, monitored virology and immunology, wrote and amended paper; RL monitored virology and immunology, amendments to paper; HP monitored PHLs Colindale tests, amendments to paper; GT was involved in clinical management of child, helpwrite and amend paper.

**Acknowledgments**

The authors wish to thank the Wellcome Trust for financial support. We thank Dr EA Hutton, Dr TM Roberts, Dr PE Wonnacott, Dr T P Rice, and Mr R McLeod, and the nurses, laboratory staff, and patients of each of the sites for their help and cooperation.

**Correspondence to:** Dr Goon

**References**


### Accepted for publication 3 April 2001

**Economic advantages of ligase chain reaction for diagnosis of genital Chlamydia trachomatis infection in GUM clinic attenders**

**Editor,**—Genital infection with *Chlamydia trachomatis* is highly prevalent and recognised as a major threat to public health. There is now a wealth of evidence to demonstrate the superiority of DNA amplification techniques over antigen detection and culture. Only one large study has directly compared ligase chain reaction (LCR) with enzyme immunoassay (EIA) on identical clinical material and no studies have analysed the health economic impact of LCR in a genitourinary medicine (GUM) clinic population.

We studied the diagnostic effectiveness and cost of LCR compared with EIA.

All GUM attendees undergoing sexual health screening were offered the opportunity to participate. Men presenting with dysuria or urethral discharge were defined as symptomatic. Swabs were collected in a prerandomised order from the cervix in female patients and 4–5 cm proximal to the urethral meatus in male patients. Urethral specimens in male patients were evaluated for evidence of urethritis (defined by >4 polymorphs per high powered field).

EIA was performed using a standard immunoassay technique (Organon Chlamydia-Tek), 1 with confirmation of reactive tests by microdot DIF. LCR (LCX system, Abbott Laboratories) was also performed on every specimen. 2 Specimens
A total of 148 male and 153 female patients were tested; 23/148 (16%) swabs from male patients were positive for Chlamydia trachomatis by LCR as the diagnostic test of choice for chlamydial infection (as in the present study), testing positive by LCR alone were retested by an alternative PCR assay for DNA sequences coding for the major outer membrane protein (MOMP) of Chlamydia trachomatis. Of 33 cases of chlamydial infection, 15 (12 (92.2%) in men and two (20.0%) in women) would have remained undetected if EIA had been used alone. Although EIA tests cost less than LCR, the inferior detection rate for EIA (17 patients screened per case detected) compared with LCR (nine patients screened per case detected) was also included in analysis of the results. The cost per case of chlamydial infection detected using EIA in this population was £65, compared with £50 for LCR.

In a hypothetical cohort of 100 GUM attendees, with an 11% prevalence of chlamydial infection (as in the present study), testing with EIA would cost £805 and would detect 6.4 of the 11 cases. Testing the cohort with LCR would cost £564 and detect all 11 cases. The additional cost of LCR is thus £199. The additional benefit is 4.6 additional cases detected. The additional cost of LCR per additional case detected is £34.

The clinic in which the study was conducted sees 6000 new attendees annually. Had EIA been used alone, 276 cases of chlamydial infection would have been missed in a one year period, at an estimated cost of over £82 000. A full economic evaluation would require that these long term health and resource costs be more thoroughly quantified and compared with other uses of NHS resources.

In summary, this study demonstrates that the overall sensitivity of LCR was double that of EIA, the previous standard diagnostic test used. Because of its improved sensitivity and increased case detection rate, the cost of LCR per case detected is equivalent to that of EIA in an urban UK GUM clinic population. Use of LCR as the diagnostic test of choice for both screening and clinical diagnosis in this setting thus represents a cost effective strategy.

AMBREEN BUTT
Department of Genitourinary Medicine and Sexual Health, Sandysford Initiative, 6 Sandysford Place, Glasgow G3 7NE, UK

www.sextransinf.com

NOTICES

International Herpes Alliance and International Herpes Management Forum
The International Herpes Alliance has introduced a website (www.herpesalliance.org) from which can be downloaded patient information leaflets. Its sister organisation the International Herpes Management Forum (website: www.IHMIF.org) has launched new guidelines on the management of herpesvirus infections in pregnancy at the 9th International Congress on Infectious Disease (ICID) in Buenos Aires.

Pan-American Health Organization, regional office of the World Health Organization
A catalogue of publications is available online (www.paho.org). The monthly journal of PAHO, the Pan American Journal of Public Health, is also available (subscriptions: pubsvc@tsp.sheridan.com).

Further details: ECEAR 2001 Conference Secretary, Division of Virology, NIBSC, Bianche Lane, South Mimms, Potters Bar, Herts, EN6 3QG, UK.

International Congress of Sexually Transmitted Infections, 24–27 June 2001, Berlin, Germany
Further details: Congress Partner GmbH, Krausenstrasse 63, D-10117, Berlin, Germany: (tel: +49-30-204 500 41; fax: +49-30-204 500 42; email: berlin@cpb.de).

1st Asia Pacific Forum on Quality Improvement in Health Care
The 1st Asia Pacific Forum on Quality Improvement in Health Care will be held from 19–21 September 2001 in Sydney, Australia. Presented by the BMJ Publishing Group (London, UK) and Institute for Healthcare Improvement (Boston, USA), with the support of the Commonwealth Department of Health and Aged Care (Australia), Safety and Quality Council (Australia), NSW Health (Australia) and Ministry of Health (New Zealand). Further details: quality@bma.org.uk; fax +44 (0) 7383 6869.

41st St Andrew’s Day Festival Symposium: First published as 10.1136/sti.77.3.223-b on 1 June 2001. Downloaded from http://sti.bmj.com/ on March 27, 2021 by guest. Protected by copyright. 41st St Andrew’s Day Festival Symposium on Therapeutics
The 41st St Andrew’s Day Festival Symposium on Therapeutics will be held on 6–7 December 2001 at the Royal College of Physicians of Edinburgh. Further details: Ms Eileen Strawn, Symposium Co-ordinator (tel: 0131 225 7324; fax: 0131 220 4393; email: esrawn@rcpe.ac.uk; website: www.rcpe.ac.uk).

10th International Congress on Behçet’s Disease will be held in Berlin 27–29 June 2002
Further details: Professor Ch Zouboulis (email: zoubbere@zedat.fu-berlin.de).

5th World Congress of Perinatal Medicine, 23–27 September 2001, Palau de Congressos de Barcelona - Avda Maria Cristina s/n, Barcelona, Spain
Further details: Dr Francesc Figueras, Congress Promotion Secretary (fax: +34.93.451.74 38; www.perinatology2001.com).

Second International Conference on Sexual Health, to be held in Bangkok, Thailand on 23–28 February 2002. Calls for abstracts deadline 1 September 2001. Further details: European Secretariat, Dr Richard Burack (tel: +44 (0) 20 8599 8029; email: siamcare@aol.com).

International Conference on HIV/AIDS 16–19 December 2001, Mumbai, India
Further details: Dr Chander P Puri, President, Indian Society for Study of Reproduction and Fertility, Institute for Research in Reproduction, Jehangir Merwanji Street, Parel, Mumbai 400012, India (Tel: 4137730 (Direct), 4132111-2-6-7; fax: 091-224-496483 or 091-022-4139412; e-mail: vicinh@bom4.vsnl.net.in OR dirrirr@vsnl.com).

10th International Symposium on Human Chlamydial Infection, 16–21 June 2002, in Antalya, Turkey
The scientific programme will encompass the breadth of chlamydial research from clinical and epidemiological studies to molecular and cell biology of all species of Chlamydia. Further details: Professor A Demir Serter, Department of Clinical Microbiology and Infectious Diseases, Ege University, Faculty of Medicine, 35100 Bornova, Izmir, Turkey (Fax: 90 232 343 71 30; e-mail: ishcic@tso.ucsf.edu).

20th World Congress of Dermatology, Paris, 1–5 July 2002
Further details: P Fournier, Colloquium, 12 rue de la Croix St Faubin, 75011 Paris, France (ref: +33 1 44 64 15 15; fax: +33 1 44 64 15 16; email: p.fournier@colloquium.com; website: www.derm-wcd-2002.com).